Sysmex (OTCMKTS:SSMXY) Issues FY 2025 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.430-0.430 for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.3 billion.

Sysmex Stock Performance

Shares of Sysmex stock traded down $0.90 during trading on Friday, hitting $8.52. 132,855 shares of the company’s stock were exchanged, compared to its average volume of 270,785. The stock has a market capitalization of $5.36 billion, a price-to-earnings ratio of 17.04 and a beta of 1.14. The business has a 50-day simple moving average of $9.74 and a 200-day simple moving average of $11.39. Sysmex has a 52-week low of $8.15 and a 52-week high of $19.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $837.32 million for the quarter, compared to analyst estimates of $819.99 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. On average, research analysts forecast that Sysmex will post 0.57 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.